# Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT04831450** · PHASE2 · WITHDRAWN · sponsor: **University of Miami**

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- HNSCC
- Squamous Cell Carcinoma of the Larynx
- Squamous Cell Carcinoma of the Oral Cavity
- Squamous Cell Carcinoma of Hypopharynx

## Interventions

- **DRUG:** Cemiplimab-Rwlc

## Key facts

- **NCT ID:** NCT04831450
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-07-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator Decision
- **Last updated:** 2022-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04831450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04831450, "Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04831450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*